Meibomian gland dysfunction (MGD) is a common eye condition and a primary cause of evaporative dry eye. Stagnation of meibum induces an unstable tear film, thus resulting in shortened tear film breakup time and superficial punctate keratopathy (SPK) in the lower cornea and punctate staining of lower bulbar conjunctiva.
Global Meibomian Gland Dysfunction Treatment Market: Overview
- Meibomian gland dysfunction (MGD) is a common eye condition and a primary cause of evaporative dry eye. Stagnation of meibum induces an unstable tear film, thus resulting in shortened tear film breakup time and superficial punctate keratopathy (SPK) in the lower cornea and punctate staining of lower bulbar conjunctiva.
- MGD is sometimes accompanied with inflammation (termed meibomitis) through the proliferation of bacteria in the meibomian gland and eyelash area. Meibomitis is strongly related to ocular surface inflammation such as corneal cellular infiltrates and neovascularization, SPK, and conjunctivitis.
- The primary reason for meibomian gland dysfunction is thought to be based on an obstructive disorder, caused by increased keratinization of the terminal ducts, the presence of squamous debris, and a thickening of the meibum
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=80012
Key Driver of Global Meibomian Gland Dysfunction Treatment Market
- Numerous pooled research studies indicated that men were more prone to meibomian gland dysfunction (MGD) than women. Accordin to Acta Ophthalmologica Journal, the prevalence of meibomian gland dysfunction in the normal population across the population in Asia is reported to be highly variable and in various studies ranges between 3.4% and 60%. It seems to be higher in the population across Asia. This high rate of prevalence is likely to drive the demand for treatment of meibomian gland dysfunction.
Request for Analysis of COVID-19 Impact on Meibomian Gland Dysfunction Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=80012
North America to Account for Major Share of Global Meibomian Gland Dysfunction Treatment Market
- In terms of region, the global meibomian gland dysfunction treatment market can be segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is projected to dominate the global market during the forecast period.
- North America is anticipated to account for a significant share of the global market due to well-defined reimbursement policies from public and private health insurance firms that help provide patients easy access to diagnosis and treatment
- According to a study published by the American Optometric Association in 2017, more than 16 million people in the U.S.-including twice as many women than men- were suffering from dry eye disease, and out of them around 70% of patients have meibomian gland dysfunction syndrome.
- Asia Pacific is expected to account for a substantial share of the market, in terms of revenue, during the forecast period due to an increase in patient population and a rise in adoption of treatment
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=80012
Key Players Operating in Global Meibomian Gland Dysfunction Treatment Market
Major players operating in the global meibomian gland dysfunction treatment market are:
- Pfizer, Inc.
- AbbVie Inc.
- Johnson and Johnson Service Inc.
- Bausch Health Companies Inc.
- Novartis AG
- RegeneRx
- Akorn, Inc.
- Sentiss Pharma Pvt. Ltd.
Pre Book Meibomian Gland Dysfunction Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=80012<ype=S
Global Meibomian Gland Dysfunction Treatment Market, by Drug Type
- Cyclosporine
- Omega-3 supplements
- Antibacterial Eye Drops
- Steroids
- AZR MD 001
- TP 03
- NOV03 (Novatears)
- HY02 – Minocycline
Read more information here:
https://www.transparencymarketresearch.com/meibomian-gland-dysfunction-treatment-market.html
Global Meibomian Gland Dysfunction Treatment Market, by Route of Administration
- Oral
- Topical
Global Meibomian Gland Dysfunction Treatment Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Browse More Trending Reports by Transparncy Market Research:
Artificial Cartilage Implant Market: https://www.transparencymarketresearch.com/artificial-cartilage-implant-market.html
Gel Stent Market: https://www.transparencymarketresearch.com/gel-stent-market.html
Preventive Medicine Market: https://www.transparencymarketresearch.com/preventive-medicine-market.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453